Search Results

You are looking at 21 - 30 of 1,101 items for :

  • "breast cancer" x
  • All content x
Clear All
Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

the express written permission of the NCCN © 2009. Disclosures for the NCCN Breast Cancer Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen

Background Since the molecular phenotypes of breast carcinomas were distinguished by gene expression patterns in 2000, breast cancer is no longer considered a single disease but rather a group of molecularly distinct neoplastic disorders. 1 – 4

Full access

Jennifer A. Ligibel

A ccumulating evidence suggests that exercise, long known to be a fundamental part of general health maintenance, may have additional benefits for breast cancer survivors. Observational evidence suggests that women who exercise after breast cancer

Full access

Nicholas Zdenkowski, Phyllis Butow, Andrew Spillane, Charles Douglas, Kylie Snook, Mark Jones, Christopher Oldmeadow, Sheryl Fewster, Corinna Beckmore, Frances M. Boyle, and for the Australia and New Zealand Breast Cancer Trials Group

For women with large or highly proliferative operable breast cancer, the decision about whether to receive neoadjuvant systemic therapy (NAST) is guided by preferences that may lead to individual patients with similar clinical circumstances choosing

Full access

Amelia B. Zelnak and Ruth M. O'Regan

Approximately two-thirds of breast cancers express either the estrogen receptor (ER), progesterone receptor (PR), or both, and this expression is predictive of benefit from endocrine therapies. 1 The use of available endocrine agents has markedly

Full access

Ingrid A. Mayer

Endocrine therapies remain the standard of care for the treatment of advanced hormone-sensitive breast cancer, but on the horizon are novel strategies that may help overcome the resistance these tumors acquire, according to Ingrid Mayer, MD, MSCI

Full access

Gayathri Nagaraj and Cynthia X. Ma

. Describe the ideal treatment with adjuvant chemotherapy for patients with estrogen receptor (ER)-positive HER2-negative lymph node-negative breast cancer. Case Report A 67-year-old otherwise healthy postmenopausal woman presented for adjuvant

Full access

Richard L. Theriault, Robert W. Carlson, Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar

: Integrate into professional practice the updates to NCCN Guidelines for Breast Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast Cancer NCCN Categories of Evidence and Consensus Category 1

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead, and Rashmi Kumar

of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Breast Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast

Full access

Arif Kamal, Tian Zhang, Steve Power, and P. Kelly Marcom

services in early-stage breast cancer (ESBC), stating, “Don't perform PET, CT, and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis.” 1 For these recommendations, the Choosing Wisely initiative defines early